This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Theragenics Reports Revenue And Earnings For Third Quarter 2012

Theragenics Corporation ® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the third quarter ended September 30, 2012.

Consolidated Results and Highlights
  • Consolidated revenue of $19.9 million in the third quarter, down 5% from 2011
  • Earnings per share
    • $0.02 in the third quarter compared to $0.03 in 2011
    • Modified Dutch auction share repurchase in July 2012 had no effect on reported EPS for third quarter 2012
  • Adjusted EBITDA of $3.2 million in the third quarter compared to $4.0 million in 2011
  • Cash flow from operations of $4.3 million in the third quarter compared to $3.6 million in 2011
  • Renewed credit facility with Wells Fargo in October 2012
    • Increased maximum available borrowings to $40 million and reduced interest rate to LIBOR plus 1.75% with maturity date of October 2015
  • Repurchased 4,761,904 common shares for $10.0 million in July 2012 pursuant to our modified Dutch auction tender offer. Total cost including transaction costs was approximately $10.4 million.
  • Cash, cash equivalents and marketable securities were $31.8 million and credit facility borrowings were $22.0 million at September 30, 2012, resulting in a net positive position of $9.8 million

Segment Results
  • Revenue
    • Surgical products revenue of $14.2 million in the third quarter, down 7% from 2011
    • Brachytherapy revenue of $5.8 million in the third quarter, down 4% from 2011
      • Incremental revenue in the Brachytherapy segment from acquired Core customers was $1.0 million in the third quarter of 2012
  • Operating income
    • Surgical products operating income of $243,000 in the third quarter, compared to $780,000 in 2011
    • Brachytherapy operating income of $906,000 in the third quarter, compared to $1.2 million in 2011


“Headwinds continue in all four of our business units,” stated M. Christine Jacobs, Chairman and CEO. “The medical device sector in which we reside is facing a triple threat of healthcare reform fallout, an impending medical device tax and macroeconomic uncertainty. Theragenics intends to weather this triple threat by continuing our plans for long term organic growth, improving profitability and conservative cash flow management.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs